Previous Close | 2.16 |
1-Year Change | -17.56% |
6-Months Change | -2.26% |
3-Months Change | -8.09% |
Moving Avg (50d) | 2.3678 |
Moving Avg (200d) | 2.3744 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 87.0M |
Beta (3-Years) | 1.33 |
Revenue Growth (ttm) | -16.77% |
Net Profit Margin (ttm) | -894.21% |
Return On Assets (ttm) | -8.69% |
EPS (ttm) | 0.49 |
PE Ratio (ttm) | 4.41 |
Dividend Yield | % |
Asset Description: | Oramed Pharmaceuticals Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-01-08 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.203 | 2.268 | 2.311 | 2.376 | 2.484 | 2.592 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.